Updates are available Correction dated 2022-02-28

Article History

Received: 2 September 2021

Accepted: 12 January 2022

First Online: 12 February 2022

Change Date: 28 February 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10637-022-01226-6

Declarations

:

: The study was approved by the Institutional Review Board and/or Ethics Committee of all the sites involved. All patients signed an Informed Consent Form before participating in the study.

: The Informed Consent Form signed by all patients included the following statement: ‘At the end of this study, the results may be published or presented. Nothing that could reveal your identity will be included in the publication or presentation.’

: All patients signed an Informed Consent Form before participating in the study.

: This study was conducted in accordance with the ethical principles of the International Council for Harmonisation guideline for Good Clinical Practice and the Declaration of Helsinki, as well as with applicable local regulations. The Clinical Study Protocol and all required associated documents were approved by the following responsible Institutional Review Boards (IRB) or Independent Ethics Committees of the individual study sites: The Western IRB, Indiana University IRB, The Washington University in St. Louis IRB, Vanderbilt University IRB, Henry Ford Health System, Greenville Health System IRB, Chesapeake IRB, Quorum Review IRB, Houston Methodist Cancer Center IRB and Christiana Care Health Services Inc. Local IRB.

: SW reports grants or contracts from the SWOG-Clinical Trials Partnership; honoraria from the American Society for Clinical Oncology (ASCO); and participation on a data safety monitoring board for the Hoosier Cancer Research Network. CR reports consulting fees from Varian, Radialogica, AstraZeneca, and EMD Serono. AJO reports grants or contracts from Adaptimmune, Alkermes, Astellas Pharma, Boston Biomedical, Bristol-Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, GlaxoSmithKline, GlycoNex, Immunocore, Incyte, Intensity Therapeutics, Kadmon, Kartos Therapeutics, Kura Oncology, Nektar, NGM Biopharmaceuticals, Oncoceutics, OncoSec, Seattle Genetics, Sound Biologics, Spring Bank, Takeda, and Targovax; and consulting fees from Array BioPharma, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, Sanofi, Pfizer, and Eisai. AS reports grants or contracts from Bristol-Myers Squibb, Mirati, Amgen, Novartis, Merck & Co, AstraZeneca, Sanofi, Abbvie, Cytomx, Macrogenics, Pfizer; and consulting fees from Mirati, Amgen, Sanofi, AstraZeneca, Merck & Co, and Bristol-Myers Squibb. MH reports no competing interests. JB reports grants or contracts to his institution from Novartis, Immunomedics, Bayer, AbbVie(Pharmacyclics), Array, Karyopharm, Lilly, Incyte, Immunomedics, Boston Biomedical, Pfizer, Symphogen, FivePrime, EMD Serono, Macrogenics, I-Mab, Dragonfly, PsiOxus; has participated in Advisory Boards for EMD Serono, AstraZeneca, Ipsen, QED, Clovis, LSK, Seattle Genetics, Bayer, Mirati, and Eisai; and has participated on data and safety monitoring boards for AstraZeneca, the Pancreatic Cancer Action Network, and Novocure. LL is an employee of Merck S.L.U., Mollet del Valles, Spain, an affiliate of Merck KGaA, Darmstadt, Germany. LS, HJ, UH, MG and AS-K are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. DC was an employee of the healthcare business of Merck KGaA, Darmstadt, Germany at the time of the study. This author is no longer an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. Current address: DMC Biopharma Sheffield, United Kingdom. ID-P was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of the study. This author is no longer an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Current address: GlaxoSmithKline, Zug, Switzerland.